Exeliom Biosciences: a new generation of microbiota-derived biotherapies
… the tumour, only 20% to 30% of cancer patients achieve a durable response to current treatments. To overcome this … a specific bacterium, Faecalibacterium prausnitzii (Fprau), was consistently absent in patients experiencing a relapse … in the journal PNAS , and now cited more than 4,000 times, established for the first time the immunomodulatory …
Published on: